BIOMARIN PHARMACEUTICAL INC (BMRN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 1.5B 3B 4.5B FY08: 296.5M FY09: 324.7M FY10: 376.3M FY11: 441.4M FY12: 500.7M FY13: 548.5M FY14: 749.3M FY15: 889.9M FY16: 1.1B FY17: 1.3B FY18: 1.5B FY19: 1.7B FY20: 1.9B FY21: 1.8B FY22: 2.1B FY23: 2.4B FY24: 2.9B FY25: 3.2B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 900M 1.8B 2.7B FY08: 244M FY09: 258.7M FY10: 306M FY11: 357.3M FY12: 408.9M FY13: 460.1M FY14: 627M FY15: 737.9M FY16: 907.2M FY17: 1.1B FY18: 1.2B FY19: 1.3B FY20: 1.3B FY21: 1.4B FY22: 1.6B FY23: 1.9B FY24: 2.3B FY25: 2.5B FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-900M -600M -300M 0 300M 600M 900M FY08: 39.8M FY09: 16.4M FY10: 544K FY11: -33.9M FY12: -110.2M FY13: -156M FY14: -92.9M FY15: -110.7M FY16: -803.4M FY17: -14.7M FY18: -123.5M FY19: -100.5M FY20: -43.4M FY21: -82.3M FY22: 161M FY23: 185.8M FY24: 484.2M FY25: 409.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-900M -600M -300M 0 300M 600M 900M FY08: 30.8M FY09: -488K FY10: 205.8M FY11: -53.8M FY12: -114.3M FY13: -176.4M FY14: -134M FY15: -171.8M FY16: -630.2M FY17: -117M FY18: -77.2M FY19: -23.8M FY20: 854M FY21: -64.1M FY22: 141.6M FY23: 167.6M FY24: 426.9M FY25: 348.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 250M 500M 750M FY08: 52.5M FY09: 65.9M FY10: 70.3M FY11: 84M FY12: 91.8M FY13: 88.4M FY14: 122.3M FY15: 152M FY16: 209.6M FY17: 241.8M FY18: 315.3M FY19: 359.5M FY20: 524.3M FY21: 470.5M FY22: 503M FY23: 532.1M FY24: 580.2M FY25: 717.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-300M 0 300M 600M 900M FY08: -9.2M FY09: 87.7M FY10: 18.7M FY11: 18.4M FY12: 17.6M FY13: -59.6M FY14: -70.4M FY15: -219.5M FY16: -227.8M FY17: -8.8M FY18: 20.2M FY19: 48.3M FY20: 85.4M FY21: 304.5M FY22: 175.9M FY23: 159.3M FY24: 572.8M FY25: 828M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-500M -250M 0 250M 500M 750M FY08: -65.5M FY09: -2.1M FY10: -30.7M FY11: -54.8M FY12: -27M FY13: -124.8M FY14: -187.5M FY15: -447.2M FY16: -376.2M FY17: -208M FY18: -124.4M FY19: -96.8M FY20: -28.9M FY21: 209M FY22: 54.9M FY23: 62.6M FY24: 487.4M FY25: 725M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 70M 140M 210M FY08: 103.6M FY09: 100.3M FY10: 125.7M FY11: 112.1M FY12: 120.3M FY14: 146.3M FY15: 160M FY16: 166.2M FY17: 174.4M FY18: 177.3M FY19: 179M FY20: 191.7M FY21: 182.9M FY22: 189M FY23: 191.6M FY24: 196.7M FY25: 197.4M FY08 FY10 FY12 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q1 '11: 1.62 Q2 '11: 1.58 Q3 '11: -0.26 Q4 '11: -0.49 Q1 '12: -0.66 Q2 '12: -0.88 Q3 '12: -0.76 Q4 '12: -0.95 Q1 '13: -1.05 Q2 '13: -0.94 Q3 '13: -1.28 Q4 '13: -1.29 Q1 '14: -1.25 Q2 '14: -1.32 Q3 '14: -0.89 Q4 '14: -0.93 Q1 '15: -1.09 Q2 '15: -1.37 Q3 '15: -2.02 Q4 '15: -1.07 Q1 '16: -1.15 Q2 '16: -3.22 Q3 '16: -2.84 Q4 '16: -3.82 Q1 '17: -3.40 Q2 '17: -1.03 Q3 '17: -0.88 Q4 '17: -0.66 Q1 '18: -0.83 Q2 '18: -0.71 Q3 '18: -0.71 Q4 '18: -0.44 Q1 '19: -0.50 Q2 '19: -0.62 Q3 '19: -0.25 Q4 '19: -0.13 Q1 '20: 0.63 Q2 '20: 0.68 Q3 '20: 4.39 Q4 '20: 4.40 Q1 '21: 4.05 Q2 '21: 4.28 Q3 '21: 0.07 Q4 '21: -0.36 Q1 '22: 0.18 Q2 '22: 0.26 Q3 '22: 0.42 Q4 '22: 0.73 Q1 '23: 0.37 Q2 '23: 0.51 Q3 '23: 0.76 Q4 '23: 0.87 Q1 '24: 1.06 Q2 '24: 1.32 Q3 '24: 1.66 Q4 '24: 2.21 Q1 '25: 2.70 Q2 '25: 3.38 Q3 '25: 2.67 Q4 '25: 1.80 Q1 '26: 1.39 Q2 '26: 0.39 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.